title: Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery.
abstract: This communication describes the synthesis and in vitro biological evaluation of novel generation 5 PAMAM dendrimers conjugated with riboflavin as a targeting ligand. Cell-based experiments demonstrated that a dendrimer conjugated with riboflavin is able to undergo cellular binding and uptake in KB cells, and when the dendrimer is also conjugated with methotrexate, the riboflavin dendrimer conjugate can potently inhibit cell growth.
authors.affiliation: Michigan Nanotechnology Institute for Medicine and Biological Sciences, Department of Internal Medicine, Division of Allergy, University of Michigan, Ann Arbor, MI 48109, USA.
authors.forename: Thommey P
authors.initials: TP
authors.lastname: Thomas
authors.forename: Seok Ki
authors.initials: SK
authors.lastname: Choi
authors.forename: Ming-Hsin
authors.initials: MH
authors.lastname: Li
authors.forename: Alina
authors.initials: A
authors.lastname: Kotlyar
authors.forename: James R
authors.initials: JR
authors.lastname: Baker
mesh_terms: D002455:Cell Division / Q000187:drug effects; D050091:Dendrimers / Q000494:pharmacology*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006367:HeLa Cells; D006801:Humans; D036103:Nanotechnology; D009369:Neoplasms / Q000188:drug therapy*; D012256:Riboflavin / Q000737:chemistry*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D050091:Dendrimers; C104700:PAMAM Starburst; D012256:Riboflavin